HighMark Wealth Management LLC Cuts Stock Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

HighMark Wealth Management LLC reduced its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 26.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,624 shares of the exchange traded fund’s stock after selling 599 shares during the quarter. HighMark Wealth Management LLC’s holdings in SPDR S&P Biotech ETF were worth $146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hartline Investment Corp increased its position in SPDR S&P Biotech ETF by 2.0% during the 3rd quarter. Hartline Investment Corp now owns 5,502 shares of the exchange traded fund’s stock valued at $544,000 after purchasing an additional 106 shares during the period. Signature Estate & Investment Advisors LLC boosted its stake in shares of SPDR S&P Biotech ETF by 5.7% during the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 2,336 shares of the exchange traded fund’s stock valued at $231,000 after purchasing an additional 125 shares in the last quarter. Denver Wealth Management Inc. boosted its stake in shares of SPDR S&P Biotech ETF by 0.9% during the 3rd quarter. Denver Wealth Management Inc. now owns 14,779 shares of the exchange traded fund’s stock valued at $1,460,000 after purchasing an additional 127 shares in the last quarter. Graypoint LLC raised its stake in SPDR S&P Biotech ETF by 5.6% in the third quarter. Graypoint LLC now owns 2,738 shares of the exchange traded fund’s stock worth $271,000 after buying an additional 146 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in SPDR S&P Biotech ETF by 0.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,873 shares of the exchange traded fund’s stock worth $2,373,000 after buying an additional 148 shares during the period.

SPDR S&P Biotech ETF Stock Performance

XBI stock opened at $91.41 on Tuesday. SPDR S&P Biotech ETF has a fifty-two week low of $81.14 and a fifty-two week high of $105.47. The company has a market capitalization of $6.97 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. The business’s 50 day moving average price is $91.63 and its two-hundred day moving average price is $96.06.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.